Is PROK or QNCX more undervalued in 2026?

CirclFi compares ProKidney Corp. (PROK) and Quince Therapeutics, Inc. (QNCX) using 13 institutional-grade valuation models. PROK has a Quality of Company score of 4.3/10 while QNCX scores 4.3/10.

Which is a better buy — PROK or QNCX?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PROK and QNCX valuations compare?

PROK at $1.83 and QNCX at $1.15 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PROK vs QNCX Valuation Comparison 2026 — Intrinsic Value Analysis

PROK

Biological Products, (No Diagnostic Substances)

ProKidney Corp.

Quality

4.3

out of 10

Value Trap

SAFE

Price

$1.83

Last close

Models

9/13

Active

QNCX

Biological Products, (No Diagnostic Substances)

Quince Therapeutics, Inc.

Quality

4.3

out of 10

Value Trap

LOW

Price

$1.15

Last close

Models

8/13

Active

Model-by-Model Comparison

Model	Type	PROK Fair Value	PROK Upside	QNCX Fair Value	QNCX Upside
Bayesian DCF	Intrinsic	$0.62	-65.9%	$2.38	+106.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$0.78	-57.6%	$4.20	+265.0%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PROK vs QNCX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PROK vs QNCX — Which Stock Is More Undervalued?

PROK scores higher with a 4.3/10 quality rating vs QNCX's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing ProKidney Corp. (PROK) and Quince Therapeutics, Inc. (QNCX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PROK currently trades at $1.83 with a QOC of 4.3/10, while QNCX trades at $1.15 with a QOC of 4.3/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).